Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Momelotinib Shows Promising JAK and ALK2 Inhibition in Myelofibrosis With Anemia

April 26th 2022

Srdan Verstovsek, MD, PhD, discusses the preliminary results of the MOMENTUM study and the potential for ALK2 inhibitor success in the larger anemia treatment landscape.

Dr. Verstovsek on the Mechanism of Action of Momelotinib in Myelofibrosis

April 25th 2022

Srdan Verstovsek, MD, PhD, discusses the mechanisms of action of momelotinib in myelofibrosis.

Targeted Treatment Arsenal for Myelofibrosis Set to Explode

April 22nd 2022

Ruben Mesa, MD, Jamile M. Shammo, MD, FASCP, FACP, Angela G. Fleischman, MD, PhD, and Stephen T. Oh, MD, PhD discuss the emerging treatment landscape in myelofibrosis.

Pacritinib May Fill Unmet Symptom Burden Need for Patients With Myelofibrosis With Moderate/Severe Thrombocytopenia

April 15th 2022

Physical function-related symptoms were prominent in the symptom burden of adult patients with myelofibrosis and moderate or severe thrombocytopenia, according to a retrospective analysis of the phase 3 PERSIST-2 study.

Combination Navitoclax and Ruxolitinib Elicits Improved Bone Marrow Fibrosis in Myelofibrosis

April 12th 2022

Navitoclax plus ruxolitinib produced an improvement in bone marrow fibrosis and a reduction in variant allele frequency in patients with myelofibrosis who progressed on or had suboptimal response with prior ruxolitinib monotherapy.

FDA Lifts Partial Clinical Hold Placed on Studies Evaluating Magrolimab in MDS and AML

April 12th 2022

The FDA has lifted a partial clinical hold that had been placed on studies examining magrolimab in combination with azacitidine following a review of comprehensive safety data collected from each trial.

Movement of Novel Agents Up Front Is Current Focus in Hematologic Cancers

April 6th 2022

Ann S. LaCasce, MD, MMSc, discusses updates in lymphoma, myelofibrosis, and chronic lymphocytic leukemia.

Dr. Garcia on the Results of the REFINE Trial in Myelofibrosis

April 5th 2022

Jacqueline S. Garcia, MD, discusses the results of the phase 2 REFINE trial in patients with myelofibrosis.

Pacritinib Paves a “Unique Lane” of Treatment for Select Myelofibrosis

April 5th 2022

Patients who develop post–essential thrombocythemia myelofibrosis or post–polycythemia vera myelofibrosis, which are associated with significant symptom burden and bone marrow failure, have limited therapies available for effective treatment.

Dr. Verstovsek on the Efficacy of Momelotinib in Myelofibrosis

April 1st 2022

Srdan Verstovsek, MD, PhD, discusses the efficacy of momelotinib in myelofibrosis.

Dr. Mesa on the Rationale for the MOMENTUM Trial in Myelofibrosis

March 31st 2022

Ruben A. Mesa, MD, discusses the rationale for the phase 3 MOMENTUM study in myelofibrosis.

Avapritinib Approved in Europe for Advanced Systemic Mastocytosis

March 25th 2022

The European Commission has expanded the current indication for avapritinib to include use as a single agent in adult patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, or mast cell leukemia, following at least 1 systemic treatment.

Clinical Pearls for Treating MPN and MF

March 7th 2022

The panel concludes this discussion with clinical pearls they would like to share with colleagues that treat MPN and MF.

Unmet Needs and Potential Advances in MPN and MF

March 7th 2022

A group of experts share unmet needs in the treatment of MPN and MF while providing information about potential advances that could impact treatment in the future.

The Clinical Course for MF and Changing Therapies

March 7th 2022

Dr Fleischman explains the clinical course she would take with MF treatment and what it would take to change therapies.

NCCN Recommends Ropeginterferon Alfa-2b in Clinical Practice Guidelines Update

March 3rd 2022

The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology have been revised to include ropeginterferon alfa-2b as a recommended treatment option for adult patients with polycythemia vera.

Dr. Mesa on the FDA Approval of Pacritinib in Intermediate- or High-Risk Myelofibrosis With Severe Thrombocytopenia

March 1st 2022

Ruben A. Mesa, MD, discusses the accelerated FDA approval of pacritinib (Vonjo) for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.

FDA Approves Pacritinib for Intermediate- or High-Risk Myelofibrosis With Severe Thrombocytopenia

March 1st 2022

The FDA has granted an accelerated approval to pacritinib (Vonjo) for the treatment of select adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.

Monitoring Patients Being Treated for MF

February 28th 2022

Dr Oh lists the ways MF can and should be monitored.

Sequencing MF Therapies and Novel Combinations

February 28th 2022

The panel relays how they would sequence MF therapies, as well as the novel combination therapies that can be used.

x